Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing ...
20d
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...
Johnson & Johnson today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in ...
Halozyme acquires Elektrofi to expand drug delivery with high-concentration biologics. Discover how this boosts growth and ...
New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared ...
Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly among children in the United States. In 2024, an estimated 3.4 million ...
February, months behind the United States and many other countries. Officials blamed a shortage of Pfizer Inc. vaccine from ...
The investments we're making to advance and expand our pipeline are increasingly translating into positive clinical results ...
Pharmaceutical Technology on MSN
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
Novo Nordisk has agreed to buy Akero Therapeutics in a deal rising to a potential $5.2bn, as the Danish drugmaker looks to solidify its recent entry into the liver disease market amid restructuring ...
Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback